Does Medicare Cover Ozempic? Part D, the $50 Bridge and 2027 Changes

    Does Medicare Cover Ozempic? Part D, the $50 Bridge and 2027 Changes

    Medicare covers Ozempic for type 2 diabetes via Part D, not for weight loss, and it is not in the $50 GLP-1 Bridge. 2026 costs and 2027 price changes.

    Written by Dr. Sheri Tomas. Updated November 11, 2026.

    Yes, Medicare covers Ozempic in 2026, but only for type 2 diabetes and its related uses, through a Medicare Part D drug plan or a Medicare Advantage plan that includes drug coverage. It does not cover Ozempic for weight loss alone, because federal law bars Medicare drug plans from paying for weight-loss drugs and Ozempic has no weight-management approval. Ozempic is also not part of the new $50-a-month Medicare GLP-1 Bridge: that program covers only Wegovy, Zepbound KwikPen and Foundayo for weight management, and it excludes people with type 2 diabetes, who are sent back to their Part D plan. As of November 2026, what you pay depends on your plan, the $615 Part D deductible and the $2,100 yearly out-of-pocket cap. A $274 negotiated price, reported by KFF and AMCP, starts on January 1, 2027. This guide explains each piece in plain English.

    Does Medicare Cover Ozempic? The Short Answer

    1. 1Yes for type 2 diabetes: Part D and Medicare Advantage drug plans can cover Ozempic for its three FDA-approved uses, all in adults with type 2 diabetes.
    2. 2No for weight loss alone: federal law prohibits Medicare drug coverage of weight-loss drugs, according to KFF (January 2026).
    3. 3Not in the $50 Bridge: the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo only, and excludes people with type 2 diabetes.
    4. 42026 costs: a $615 deductible and a $2,100 out-of-pocket cap on covered Part D drugs (CMS).
    5. 52027 changes: a $274 negotiated price for semaglutide (KFF, AMCP) and a $675 list price for Ozempic (Novo Nordisk), both from January 1, 2027.

    Does Medicare Cover Ozempic in 2026?

    Yes, when it is prescribed for an FDA-approved use. According to the FDA label revised in May 2026, Ozempic injection is approved for adults with type 2 diabetes for three purposes: to improve blood sugar control alongside diet and exercise; to lower the risk of major heart events such as heart attack and stroke in people who also have heart or blood vessel disease; and to lower the risk of worsening kidney function, kidney failure and death from heart causes in people who also have chronic kidney disease. Novo Nordisk announced the kidney approval on January 28, 2025 (PharmExec). More on these uses is in Ozempic for diabetes and Ozempic and heart health.

    Ozempic is widely used in Medicare. KFF reported in January 2026 that about 2 million Part D enrollees used Ozempic in 2024, up from fewer than 150,000 in 2019. Gross Part D spending on GLP-1 drugs reached $27.5 billion in 2024, and Ozempic accounted for 47% of it. Coverage still depends on your plan's list of covered drugs, called a formulary.

    Why Won't Medicare Pay for Ozempic for Weight Loss?

    Two reasons. First, the law: KFF notes that Medicare coverage of GLP-1 drugs for weight loss is prohibited by statute, and AARP traces this exclusion to the 2003 law that created Part D. Second, the label: Ozempic has no weight-management approval at all. The semaglutide brand approved for weight management is Wegovy. A Part D plan can refuse to pay for Ozempic without a covered diagnosis such as type 2 diabetes. See is Ozempic approved for weight loss and Ozempic vs Wegovy for how the two brands differ.

    Is Ozempic Part of the $50 Medicare GLP-1 Bridge?

    No. This is the most common point of confusion. The Medicare GLP-1 Bridge is a temporary program that, according to CMS, runs from July 1, 2026 through December 31, 2027 with a $50 copay per month. The Medicare.gov fact sheet (Product No. 12234, June 2026) lists the covered drugs as Foundayo tablets, Wegovy (injection or tablet) and Zepbound KwikPen only. Ozempic is not on the list.

    The same fact sheet excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea or fatty liver disease, anyone whose plan already covers a GLP-1, and people enrolled only in private fee-for-service, cost or PACE plans. So if you take Ozempic for diabetes, the Bridge does not change your coverage or costs.

    Who Qualifies for the Medicare GLP-1 Bridge?

    The Bridge is for weight management in people without diabetes who meet body mass index (BMI) rules. According to the Medicare.gov fact sheet, you may qualify with:

    1. 1A BMI of 35 or higher
    2. 2A BMI of 30 or higher plus heart failure, uncontrolled high blood pressure, or chronic kidney disease stage 3a or worse
    3. 3A BMI of 27 or higher plus prediabetes, or a past heart attack, stroke or peripheral artery disease

    CMS says the $50 copay does not count toward your Part D out-of-pocket total, the Part D deductible does not apply, Extra Help (the Low-Income Subsidy) does not lower it, and a single central processor handles prior approval and claims. KFF Health News, via NPR in May 2026, reported that Humana is the CMS contractor for prior approval. Pharmacy Times (July 2026) reported that Medicare Advantage drug plan members are eligible. KFF estimated in June 2026 that about 3.8 million beneficiaries met the rules, using 2023 data. How Wegovy and Zepbound compare with Ozempic is covered in Zepbound vs Ozempic.

    How three GLP-1 drugs are treated by Medicare, as of November 2026

    Question
    Ozempic
    Wegovy
    Zepbound

    FDA-approved for type 2 diabetes uses

    Yes (glucose, heart and kidney risk in T2D)

    No

    No

    Part D coverage for weight loss alone

    No (prohibited by law)

    No (prohibited by law)

    No (prohibited by law)

    In the $50 GLP-1 Bridge (Jul 2026 to Dec 2027)

    No

    Yes (injection or tablet)

    Yes (KwikPen only)

    Bridge open to people with type 2 diabetes

    Not applicable

    No

    No

    2027 Medicare negotiated price (from Jan 1, 2027)

    $274 per 30 days for semaglutide; $276.78 for the 4 mg/3 mL pen

    $274 for semaglutide; $385.63 for 2.4 mg x4

    Not reported in the sources we used

    How Much Is Ozempic With Medicare Part D in 2026?

    Your cost depends on your plan's formulary tier and cost-sharing, but the federal limits are set by CMS. For 2026, the standard Part D deductible is $615 and the out-of-pocket threshold, often called the cap, is $2,100, up from $2,000 in 2025 (CMS fact sheet, April 2025). The deductible is what you may pay before the plan shares costs. You then pay a copay or coinsurance (a percentage of the price) until your spending on covered drugs reaches $2,100, after which covered Part D drugs cost nothing more that year.

    Consumer guides from NerdWallet and Humana list Ozempic at about $1,027.51 per month before insurance; this is a secondary figure, and your plan's negotiated cost may differ. If paying large amounts early in the year is hard, the Medicare Prescription Payment Plan lets you spread Part D costs into monthly payments; ask your plan to enroll. For prices outside Medicare, see how much Ozempic costs per month in 2026.

    Does Ozempic Part D Coverage Require Prior Authorization?

    Often, but it varies by plan. AARP (August 2026) notes that plans may require step therapy, meaning you try a cheaper drug such as metformin first, and documentation of a type 2 diabetes diagnosis before they approve Ozempic. This is called prior authorization. We found no dated figure on how many plans do this, so check your own formulary. If a request is denied, your prescriber can ask for an exception and you can appeal. General tips on insurance approvals are in does insurance cover Ozempic.

    Does Medicare Advantage Cover Ozempic Differently?

    The core rules are the same. A Medicare Advantage plan with drug coverage (an MA-PD) follows the same Part D law: it can cover Ozempic for type 2 diabetes uses and cannot cover it for weight loss alone. The same $615 deductible and $2,100 cap apply to covered drugs in 2026. Differences come from the plan: its formulary tier, prior authorization rules and pharmacy network. MA-PD members can use the GLP-1 Bridge for Wegovy, Zepbound or Foundayo if they meet the rules, but that does not help anyone taking Ozempic for diabetes.

    What Is Medicare's Negotiated Price for Ozempic in 2027?

    Semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, was one of 15 drugs in the second round of Medicare drug price negotiation. According to KFF (November 2025) and an AMCP summary of CMS data (December 2025), the negotiated price, called the maximum fair price, is $274 for a 30-day supply, compared with a 2024 list price of $959, a cut of about 71%. AMCP lists $276.78 for the Ozempic 4 mg/3 mL pen. It takes effect on January 1, 2027. AMCP reports 2.28 million Part D enrollees used semaglutide, with $15.16 billion in gross 2024 spending.

    The $274 figure is the price Medicare plans pay, not your copay. No source we found gives a dollar figure for what beneficiaries will actually pay for Ozempic under it. Separately, a November 6, 2025 White House agreement announced a $245 Medicare and Medicaid price for Ozempic, Wegovy, Zepbound and Mounjaro, as reported by AJMC; KFF says it is unclear how that price interacts with the $274 negotiated price.

    What Else Changes for Ozempic Medicare Coverage in 2027?

    Several changes start on January 1, 2027. Novo Nordisk announced in February 2026 that the list price of Ozempic 0.5, 1 and 2 mg will drop to $675 per month, about 35% lower, with similar list-price cuts for Wegovy and Rybelsus 7 and 14 mg. Plan sources UnitedHealthcare and Optum report that the Part D out-of-pocket cap will rise to $2,400 and the deductible to $700 in 2027; we could not confirm these figures in a CMS document, so treat them as provisional. CMS announced on July 28, 2026 that the 2027 Part D base beneficiary premium is $41.33; your actual premium depends on your plan.

    Ozempic and Medicare Part D: 2025 to 2027 timeline

    Item
    2025
    2026
    2027

    Part D out-of-pocket cap

    $2,000 (CMS)

    $2,100 (CMS)

    $2,400 (UHC, Optum; not confirmed by CMS)

    Standard deductible

    Not covered here

    $615 (CMS)

    $700 (UHC, Optum; not confirmed by CMS)

    Medicare negotiated price, semaglutide

    None

    None

    $274 per 30 days from Jan 1 (KFF, AMCP)

    Ozempic list price per month

    About $1,028 (secondary)

    About $1,028 (secondary)

    $675 from Jan 1 (Novo Nordisk)

    $50 GLP-1 Bridge (excludes Ozempic)

    None

    From July 1

    Through December 31

    What About the Ozempic Pill (Formerly Rybelsus)?

    Novo Nordisk now labels oral semaglutide tablets under the Ozempic name, according to its prescribing information page (August 2026). Epocrates reported in February 2026 that Rybelsus is being renamed the Ozempic Pill in 1.5, 4 and 9 mg strengths, with a US launch planned for the second quarter of 2026. We could not confirm whether it has launched under the new name or how Part D plans list it, and Novo's price announcement still refers to Rybelsus 7 and 14 mg. Check your formulary under both names. Background is in Ozempic tablets.

    What Happens After the Bridge Ends in December 2027?

    Nothing has been confirmed. CMS extended the Bridge through 2027 because the BALANCE Model, a planned longer-term approach to obesity drug coverage, will not launch on January 1, 2027 (CMS; KFF, April 2026). What replaces the Bridge after December 31, 2027 has not been announced. For Ozempic users with type 2 diabetes, Part D coverage continues regardless.

    When to Talk to Your Doctor

    1. 1Your Part D plan denies Ozempic or asks for step therapy or diagnosis records.
    2. 2You are taking Ozempic without a type 2 diabetes diagnosis and expect Medicare to pay.
    3. 3You are considering switching to Wegovy or Zepbound to use the Bridge; this is a medical decision, not only a cost one.
    4. 4You cannot afford your copay and are thinking of skipping doses or stopping.
    5. 5You have heart or kidney disease and want to know whether Ozempic's approved uses apply to you.

    Questions to Ask Your Doctor or Plan Before You Fill

    1. 1Is Ozempic on my plan's formulary, and on which tier?
    2. 2Does my plan require prior authorization or step therapy for Ozempic?
    3. 3What will I pay per month before and after the $615 deductible in 2026?
    4. 4Should I enroll in the Medicare Prescription Payment Plan to spread costs?
    5. 5Will my cost change on January 1, 2027, when the $274 negotiated price and $675 list price take effect?
    6. 6If I do not have diabetes, am I eligible for the GLP-1 Bridge with a different drug?

    If you are just starting treatment, see how to get prescribed Ozempic.

    The Bottom Line

    Medicare covers Ozempic in 2026 for type 2 diabetes and its heart and kidney uses through Part D or Medicare Advantage drug plans, but not for weight loss alone. Ozempic is not part of the $50 GLP-1 Bridge, which covers only Wegovy, Zepbound KwikPen and Foundayo and excludes people with type 2 diabetes. In 2026 costs are limited by the $615 deductible and $2,100 cap. From January 1, 2027, a $274 negotiated price and $675 list price take effect, but your own copay will depend on your plan.

    FAQ

    No. Federal law bars Medicare drug plans from covering weight-loss drugs, and Ozempic has no weight-management approval. It is covered only for type 2 diabetes uses.

    No. The Bridge covers Wegovy, Zepbound KwikPen and Foundayo for weight management only, and excludes people with type 2 diabetes, according to Medicare.gov (June 2026).

    It depends on your plan. In 2026 the standard deductible is $615 and out-of-pocket costs for covered drugs are capped at $2,100 for the year (CMS).

    KFF and AMCP report a negotiated price of $274 for a 30-day supply of semaglutide, starting January 1, 2027. This is what plans pay, not your copay.

    Yes, if the plan includes drug coverage and you have a type 2 diabetes use. The same Part D rules, deductible and cap apply, but formularies and approval rules differ by plan.

    Prices fall from January 1, 2027, with a $274 negotiated price and a $675 list price. No source yet gives a dollar figure for what beneficiaries will pay.

    Sources

    1. 1Novo Nordisk. Ozempic (semaglutide) injection prescribing information, US Food and Drug Administration, 2026
    2. 2CMS. Final CY 2026 Part D redesign program instructions, CMS, 2025
    3. 3CMS. Medicare GLP-1 Bridge, CMS, 2026
    4. 4Medicare.gov. Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month (Product No. 12234), CMS, 2026
    5. 5CMS. Annual release of Part D national average monthly bid amount and other Part C & D bid information (July 28, 2026), CMS, 2026
    6. 6CMS delivers savings for seniors on 15 major drugs for cancer and chronic disease, CMS, 2025
    7. 7KFF. Recent trends in GLP-1 use and spending in Medicare, KFF, 2026
    8. 8KFF. Understanding the Trump administration's negotiated drug prices for Medicare, KFF, 2025
    9. 9KFF. Nearly four million Medicare beneficiaries could be eligible for the temporary Medicare GLP-1 Bridge program, KFF, 2026
    10. 10KFF. CMS extends Medicare's short-term bridge program for GLP-1 obesity drug coverage, KFF, 2026
    11. 11AMCP. Federal update: CMS releases negotiated prices for 15 drugs under Medicare Drug Price Negotiation Program, Academy of Managed Care Pharmacy, 2025
    12. 12Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus, BioSpace (press release), 2026
    13. 13KFF Health News. Some Medicare beneficiaries can now get popular obesity drugs for $50 a month, NPR, 2026
    14. 14Medicare's new GLP-1 Bridge program: what pharmacists need to know before dispensing, Pharmacy Times, 2026
    15. 15Trump announces deals with Lilly, Novo to cut weight loss drug prices, AJMC, 2025
    16. 16FDA approves Novo Nordisk's Ozempic to reduce kidney disease in patients with type 2 diabetes, chronic kidney disease, Pharmaceutical Executive, 2025
    17. 17Rybelsus to be rebranded as Ozempic pill, Epocrates, 2026

    This article is general information, not insurance or medical advice; check your own plan's formulary and talk to your doctor. Ozempic is made by Novo Nordisk, and some figures come from company announcements.

    Dr. Sheri Tomas

    Author

    Published November 10, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    How Does Ozempic Work?